Besides pursuing with the clinical development of new treatments, an important goal of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms (MPNs) is to educate physicians, patients, caregivers, and the community at large about novel, promising MPN medications and findings from the latest clinical research studies.
We periodically publish the patient-centered newsletter MPN Focus (current and past issues are available in the panel below), in which we present all the active clinical trials evaluating emerging MPN medications in clinical development at MD Anderson and highlight the most important findings from MPN clinical research studies. These studies are presented at the national and international hematology/oncology conferences, such as the American Society of Hematology, the American Society for Clinical Oncology, the Society of Hematologic Oncology, and the European Hematology Association.
In addition, we periodically publish the newsletter Leukemia Insights (current and past issues are available in the panel below) to inform physicians and the broader community about the active clinical trials on MPN medications in clinical development at MD Anderson.
We frequently engage in educational symposia and conferences for physicians and patients; for example, from 2013 to 2017, we organized and hosted five annual MPN Patient Meetings at MD Anderson, in collaboration with the patient support groups (photo to the left, 2013 Meeting). Other educational activities that the MPN Team engages in include video presentations on novel MPN treatments at online forums, such as Patient Power, PV Reporter, and others; and invited presentations at the annual meetings of ASH, EHA, SOHO, ASCO, the Texas MPN Workshops, and many others.
LEARN MORE: Educational videos on Myeloproliferative Neoplasms (myelofibrosis, polycythemia vera and essential thrombocytemia) for patients
LEARN MORE: Educational podcast "A Deep Dive into Myelofibrosis"
LEARN MORE: Educational interviews for patients/caregivers on the latest MPN treatments at "The Patient Story":
- Novel Treatments in Development for Myelofibrosis
- Novel Treatments in Development for Polycythemia Vera
- Novel Treatment for Myeloid Lymphoid Neoplasms with FGFR1 rearrangement (MLNFGFR1). Pemigatinib was approved as a treatment for MLNFGFR1 on August 26, 2022. Please visit our web page on MPN Research and Treatments and review our MPN Focus Winter 2022-23 newsletter posted below for more details.
- "New Developments in MPN Research 2023".
It is a very exciting time in the field of MPNs in light of the recent approvals of two MPN medications and the array of other medications in advanced clinical development. We are very optimistic that these novel treatment options will substantially improve the quality of life and the outcomes of MPN patients and transform the field of MPNs in the near future!
Clinical Research Center for MPNs Team
Overview of Myeloproliferative Neoplasms